62results about How to "Improve muscle function" patented technology

The present invention provides methods for using growth hormone releasing factor analogs of the formula (A), X-GRF Peptide, and pharmaceutically acceptable salts thereof, for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.

The invention relates to the use of a chemical substance selected from the group consisting of N-′2-hydroxy-3-(1-piperidinyl)-propoxyl 1-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixtures of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compounds in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.

Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy. One aspect the disclosure provides an isolated antisense polynucleotide wherein the polynucleotide specifically hybridizes to an exon target region of a gamma sarcoglycan RNA, wherein the exon is selected from the group consisting of exon 4 (SEQ ID NO:1), exon 5 (SEQ ID NO: 2), exon 6 (SEQ ID NO: 3), exon 7 (SEQ ID NO: 4) and a combination thereof. In some embodiments, the antisense polynucleotide cannot form an RNase H substrate, and in further embodiments the antisense polynucleotide comprises a modified polynucleotide backbone.

The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.

The device is embodied in four variants. The home chair comprises a three-dimensional frame with a seat pivotally connected thereto in such a way that it is tiltable forward and up-and-down, a seat arresting device, a smooth displacement compensator, a reset mechanism embodied in the form of an oil-gas damper and a backrest, the tilt angle with respect to the seat is less than 90° and the distance between the top edge and the seat is less than 250 mm. The school variant is provided with a smooth displacement compensator and a reset mechanism embodied in the form of a spring. The child variant is adjustable in the vertical and horizontal planes, thereby making it possible to select the optimal sitting parameters of a child during the growth thereof, and comprises a seat provided with a tilt angle adjusting unit, a smooth displacement compensator and a reset mechanism.

A method for enhancing muscle function of skeletal muscles in connection with a planned spine surgery intervention in a patient's back is provided. The method includes implanting one or more electrodes in or adjacent to tissue associated with one or more skeletal muscles within a back of a patient, the one or more electrodes in electrical communication with a pulse generator programmed for enhancing muscle function of the one or more skeletal muscles. Electrical stimulation is delivered, according to the programming during a time period associated with the planned spine surgery intervention, from the pulse generator to the tissue associated with the one or more skeletal muscles via the one or more electrodes, thereby improving neuromuscular control system performance of the one or more spine stabilizing muscles in connection with the planned spine surgery intervention to reduce the patient's recovery time associated with the planned spine surgery intervention.

The present invention relates to a medical device comprising an artificial contractile structure which may be advantageously used to assist the functioning of a hollow organ. Said medical device comprises an artificial contractile structure comprising at least one contractile element (100) adapted to contract an organ, in such way that said contractile element (100) is in a resting or in an activated position, at least one actuator designed to activate said contractile structure, and at least one source of energy for powering said actuator. The ratio 'current which is needed to maintain the contractile element in its activated position / current which is needed to change the position of the contractile element' is less than 1 / 500, preferably less than 1 / 800, and more preferably less than 1 / 1000.

The present disclosure relates to the treatment of muscle conditions, such as SMA, with the use of an agent that inhibits myostatin signaling. The disclosure includes combination therapies that include a myostatin inhibitor and a neuronal corrector.

The invention relates to the use of a chemical substance selected from the group consisting of N-′2-hydroxy-3-(1-piperidinyl)-propoxyl 1-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixtures of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compounds in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.